Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 8/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.44 |
| ▸ | HPGD | P15428 | 6/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | SERPINH1 | P50454 | 1/20 | 0.43 |
| ▸ | GLA | P06280 | 3/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | NQO2 | P16083 | 2/20 | 0.41 |
| ▸ | CASP1 | P29466 | 1/20 | 0.41 |
| ▸ | CASP7 | P55210 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | CFTR | P13569 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19776258 | 1.00 | ABL1 (0.51) | ABL1KDM4EPOLBGAAALDH1A1 | |
| SCHEMBL140598 | 0.82 | KDM4E (0.61) | ABL1KDM4EPOLBGAAALDH1A1 | |
| SCHEMBL29562450 | 0.82 | KDM4E (0.49) | ABL1KDM4EPOLBGAAALDH1A1 | |
| SCHEMBL505256 | 0.82 | ABL1 (0.64) | ABL1KDM4EPOLBGAAALDH1A1 | |
| SCHEMBL1119372 | 0.82 | KDM4E (0.49) | ABL1KDM4EPOLBGAAALDH1A1 | |
| SCHEMBL25213358 | 0.81 | KDM4E (0.51) | ABL1KDM4EPOLBGAAALDH1A1 | |
| SCHEMBL1056378 | 0.81 | ABL1 (0.53) | ABL1KDM4EPOLBGAAALDH1A1 | |
| SCHEMBL3203329 | 0.81 | ABL1 (0.45) | ABL1KDM4EPOLBGAAMAPT | |
| SCHEMBL1003428 | 0.81 | ABL1 (0.53) | ABL1KDM4EPOLBGAAALDH1A1 | |
| SCHEMBL31636871 | 0.81 | ABL1 (0.45) | ABL1GAAALDH1A1MAPTSERPINH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4308229-A1 | INHIBITORS OF PLASMA KALLIKREIN | Takeda Pharmaceutical Company Limited (JP) | 2024-01-24 | — | — | EP | disclosed |
| US-20230088326-A1 | PROCESS FOR PREPARATION OF ARTHROPODICIDAL ANTHRANILAMIDE COMPOUNDS | UPL LTD (IN) | 2023-03-23 | — | — | US | disclosed |
| WO-2022197763-A1 | INHIBITORS OF PLASMA KALLIKREIN | SHIRE HUMAN GENETIC THERAPIES, INC. (US) | 2022-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230088326-A1 | PROCESS FOR PREPARATION OF ARTHROPODICIDAL ANTHRANILAMIDE COMPOUNDS | ANTXR2, APEH, TYR | ABL1 68/4885KDM4E 1445/4885POLB 2371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.